NCT00627120View on ClinicalTrials.gov

Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

September 30, 2008

Conditions
Healthy
Interventions
DRUG

VGX-1027

Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.

Trial Locations (1)

21201

SNBL Clinical Pharmacology Center, Baltimore

Sponsors
All Listed Sponsors
collaborator

GeneOne Life Science, Inc.

INDUSTRY

lead

VGX Pharmaceuticals, LLC

INDUSTRY

NCT00627120 - Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects | Biotech Hunter | Biotech Hunter